Gilead Sciences bets $2.2bn on immune reset with Ouro Medicines BCMAxCD3 bispecific acquisition

Gilead Sciences (Nasdaq: GILD) has entered a definitive agreement to acquire Ouro Medicines, a privately held San Francisco-based clinical-stage biotechnology company, for $1.675 billion in upfront cash consideration and up to $500 million in contingent milestone payments. The deal centres on OM336, known as gamgertamig, a BCMAxCD3 bispecific T cell engager that has shown early but compelling evidence of deep B cell depletion and potential immune reset in severe antibody-mediated orphan diseases. Concurrently, Gilead Sciences is in advanced discussions with Belgian biotech Galapagos (Euronext and Nasdaq: GLPG) on a research and development collaboration that would see Galapagos absorb half the acquisition cost, take on Ouro’s operating assets and employees, and share development responsibilities through registrational studies. The transaction signals Gilead’s intent to expand its inflammation franchise into next-generation immunology, where T cell engager platforms are emerging as a credible alternative to both chronic immunosuppression and complex cell therapies.

What is OM336 gamgertamig and how does it work as a BCMAxCD3 T cell engager for autoimmune disease?

OM336, or gamgertamig, is a bispecific antibody that simultaneously binds BCMA on plasma cells and CD3 on T cells, effectively redirecting the patient’s own immune system to destroy the autoantibody-producing cells that drive many inflammatory diseases. BCMA, or B cell maturation antigen, is a receptor expressed predominantly on long-lived plasma cells residing deep in bone marrow niches. These cells are critical to sustaining pathogenic antibody production in diseases such as autoimmune hemolytic anemia and immune thrombocytopenia, and they are precisely the populations that CD19-targeted therapies can fail to eliminate. By engaging T cells through CD3, the agent does not require manufacturing personalised cellular products as CAR-T therapies do, which meaningfully simplifies treatment logistics and widens the eligible patient population.

In ongoing Phase 1/2 studies, gamgertamig has been administered subcutaneously in a limited treatment course, with early data in AIHA and ITP suggesting both rapid and deep B cell depletion and, in a subset of patients, durable remission without ongoing immunosuppression. This concept of immune reset is increasingly discussed in the scientific literature as the aspirational endpoint for autoimmune therapy, representing a fundamental departure from the indefinite chronic treatment models that currently dominate the standard of care. The FDA has granted gamgertamig both Fast Track and Orphan Drug Designation for AIHA and ITP, and Gilead Sciences plans to initiate registrational studies in 2027.

Why is Gilead Sciences expanding into T cell engager autoimmune therapies alongside its existing CAR-T portfolio?

Gilead Sciences already operates in the CAR-T space through its oncology assets Yescarta and Tecartus, giving it institutional familiarity with cell and immune-modulating therapies. However, CAR-T platforms carry substantial cost, logistical, and safety complexity that limits their accessibility. T cell engager platforms represent what might be described as a more tractable deployment route: they are manufactured as off-the-shelf biologic drugs, administered subcutaneously, and do not require hospital-based infusion infrastructure at the same scale as CAR-T. For Gilead Sciences, which reported full-year 2025 revenue of $29.4 billion with significant cash generation, the addition of an early-stage but scientifically differentiated platform in inflammation diversifies its revenue base beyond the HIV franchise that still accounts for the majority of product sales.

The Ouro acquisition also follows Gilead’s $7.8 billion agreement to acquire Arcellx and its multiple myeloma cell therapy candidate anito-cel, signalling a deliberate strategy of stacking differentiated immune-modulating assets across both oncology and inflammatory disease. The two acquisitions together make Gilead Sciences one of the more vertically positioned operators in the BCMA-targeting space, where the target is now validated across haematological cancers, autoimmune orphan diseases, and potentially a much broader universe of antibody-mediated inflammatory conditions.

How does the Galapagos collaboration structure change the financial risk profile of the Ouro Medicines deal for Gilead?

The contemplated arrangement with Galapagos substantially alters the net capital outlay for Gilead Sciences. Under the terms under discussion, Galapagos would contribute 50% of the $1.675 billion upfront consideration and 50% of any milestone payments, reducing Gilead’s effective cash deployment to approximately $838 million upfront. Galapagos would absorb Ouro Medicines’ operating assets and retain its employee base, effectively outsourcing the day-to-day development organisation to the Belgian company. Development costs through registrational study initiation would sit primarily with Galapagos, with costs splitting equally once registrational trials begin. Gilead Sciences would retain sole worldwide commercialisation rights outside Greater China, paying Galapagos royalties of 20% to 23% of net sales.

The arrangement also contemplates amendments to the existing Option License and Collaboration Agreement between the two companies, freeing up to $500 million of Galapagos’s current cash for discretionary use, including up to $150 million for potential share repurchases. This is a meaningful concession to Galapagos shareholders who have watched the stock trade at a deep discount to its cash reserves following a series of clinical and strategic setbacks, including the wind-down of its cell therapy operations announced in early 2026. For Galapagos, the transaction restores operational purpose and R&D pipeline exposure that its own internal programmes have failed to provide at scale. Whether this collaboration is finalised remains subject to negotiation, and investors should note that it is described as advanced discussions rather than a binding agreement.

How does the BCMA T cell engager competitive landscape look for Gilead Sciences and gamgertamig going into registrational studies?

The BCMA-targeting space in autoimmune disease is nascent but gaining rapid scientific validation. Teclistamab, a BCMAxCD3 bispecific antibody developed by Johnson and Johnson for multiple myeloma, has been administered off-label and under compassionate use in autoimmune settings including refractory systemic lupus erythematosus, systemic sclerosis, Sjogren’s syndrome, and immune thrombocytopenia. Early case series published in the New England Journal of Medicine and conference data from the American College of Rheumatology suggest plasma cell targeting via BCMA is both feasible and clinically meaningful in autoimmune disease, including in patients who previously failed CD19-targeted CAR-T therapy. This is a critical nuance: BCMA captures a layer of long-lived plasma cells in bone marrow that CD19 therapies miss entirely, suggesting gamgertamig is not simply competing with existing biologic agents but addressing a previously unreachable biological compartment.

Johnson and Johnson is the most credible near-term competitor given its BCMA experience in oncology and the accumulating compassionate use data for teclistamab in autoimmune settings. AbbVie, through its BCMA-directed pipeline assets and its broad autoimmune franchise, also represents a potential future competitor. Novartis and Bristol-Myers Squibb are active in the CD19 T cell engager space in autoimmune disease, with Novartis’s ianalumab and BMS’s deucravacitinib occupying adjacent mechanistic territory. None of these, however, is pursuing the combination of subcutaneous administration, limited treatment course design, and dedicated clinical development in orphan antibody-mediated diseases with the specificity that gamgertamig currently represents. That specificity, combined with FDA-granted designations, gives Gilead Sciences a regulatory head start in AIHA and ITP even if the broader autoimmune opportunity remains contested.

What does the Gilead Sciences GILD share price trajectory tell us about market sentiment toward its acquisition strategy?

Gilead Sciences shares have had a strong twelve-month run ahead of this announcement. The stock reached an all-time closing high of approximately $154.92 in February 2026, with a 52-week range of $93.37 to $157.29. As of March 20, 2026, Gilead Sciences was trading around $138 to $141, reflecting some pullback from the peak but still representing a significant re-rating from where it was twelve months earlier. The market capitalisation stands at approximately $170 billion, giving Gilead Sciences the financial headroom to execute multiple portfolio-building transactions without material balance sheet stress. Full-year 2025 results showed non-GAAP diluted earnings per share of $8.15 against revenue of $29.4 billion, with the Biktarvy HIV franchise contributing $14.3 billion alone.

The acquisition premium implied in the Ouro transaction is harder to assess without a public comparator, given Ouro Medicines was founded only in 2025 and has not disclosed revenue figures. What the $1.675 billion upfront price does indicate is that Gilead Sciences and its advisers at Centerview Partners and TD Cowen view the early Phase 1/2 data as sufficiently differentiated to justify a significant pre-registrational bet. The consensus analyst price target for Gilead Sciences sits around $157, with 23 analysts holding buy ratings. The stock’s beta of approximately 0.24 reflects its defensive characteristics, meaning the market is unlikely to punish Gilead Sciences sharply for a deal of this scale provided the development narrative holds.

What are the key execution and development risks Gilead Sciences faces in translating early gamgertamig data into a registrational programme?

The most immediate risk is clinical. Phase 1/2 data in small, severely ill patient populations can look compelling precisely because selection bias is high and follow-up is short. The AIHA and ITP patient groups reported to date appear to represent refractory or severe disease where the intervention-to-response signal is strong, but registrational studies will need to demonstrate both efficacy and durability in broader, less selected populations against the relevant standard of care. The immune reset concept, while scientifically appealing, requires multi-year follow-up to confirm whether durable drug-free remission is achievable at scale or whether the initial responses are followed by autoantibody rebound as occurs in some CD19 CAR-T data sets.

Safety is a second critical axis. BCMA-targeted T cell engagers in oncology settings, including teclistamab, are associated with cytokine release syndrome, infections related to hypogammaglobulinaemia, and on-target off-tumour effects. In autoimmune patients who may be less heavily pretreated and who typically have better performance status than relapsed refractory myeloma patients, the risk-benefit calculus is different. Any severe safety signal in the registrational programme would materially impair the asset’s commercial trajectory and potentially allow competing platforms to establish clinical precedence. The collaboration structure with Galapagos adds a layer of execution complexity: two companies co-developing a single asset across separate organisational cultures and regulatory jurisdictions historically introduces coordination costs and potential strategic misalignment at critical junctures.

Key takeaways: what the Gilead Sciences acquisition of Ouro Medicines means for pharma, biotech, and autoimmune therapy markets

• Gilead Sciences has agreed to acquire Ouro Medicines for $1.675 billion upfront and up to $500 million in milestones, adding gamgertamig (OM336), a BCMAxCD3 bispecific T cell engager for autoimmune disease, to its inflammation portfolio.
• Gamgertamig holds FDA Fast Track and Orphan Drug Designation for autoimmune hemolytic anemia and immune thrombocytopenia, with registrational studies planned for 2027, providing a defined near-term development catalyst.
• The Galapagos collaboration under discussion would halve Gilead’s effective cash outlay to approximately $838 million upfront, with Galapagos absorbing operational assets and co-funding development through the registrational phase in exchange for 20% to 23% royalties on net sales.
• BCMA-targeted T cell engagers address long-lived plasma cells in bone marrow that are inaccessible to CD19-targeted therapies, positioning gamgertamig as complementary to rather than competing with CAR-T assets in Gilead’s existing oncology portfolio.
• The transaction continues a rapid build-out of Gilead’s BCMA franchise, following the $7.8 billion Arcellx acquisition for the anito-cel multiple myeloma cell therapy program.
• Johnson and Johnson represents the most credible near-term competitive threat given its BCMA experience with teclistamab and accumulating compassionate use data in autoimmune settings; Gilead’s orphan designations and subcutaneous limited-course design offer differentiation.
• Key execution risks include translating small-population Phase 1/2 signals into broad registrational success, managing the safety profile of BCMA depletion in autoimmune rather than oncology populations, and coordinating a complex two-partner development structure with Galapagos.
• For Galapagos shareholders, the arrangement could restore a meaningful R&D purpose following the wind-down of its cell therapy operations, while the freed cash allowance of up to $500 million including $150 million for buybacks addresses the persistent cash discount in GLPG’s valuation.
• The deal is the most concrete signal yet from the biopharmaceutical industry that the immune reset concept, achieving durable drug-free remission through targeted lymphodepletion rather than chronic suppression, is now attracting large-scale commercial investment.
• Broader competitive implications point toward accelerated deal activity in the T cell engager and plasma cell-targeting space as large-cap pharma firms seek to replicate or defend ground in what may become the defining immunology platform of the late 2020s.